NO985820L - Cytokinproduksjonsinhibitor, triazepinforbindelse og mellomprodukter for disse - Google Patents

Cytokinproduksjonsinhibitor, triazepinforbindelse og mellomprodukter for disse

Info

Publication number
NO985820L
NO985820L NO985820A NO985820A NO985820L NO 985820 L NO985820 L NO 985820L NO 985820 A NO985820 A NO 985820A NO 985820 A NO985820 A NO 985820A NO 985820 L NO985820 L NO 985820L
Authority
NO
Norway
Prior art keywords
cytokine production
heteroaryl
aryl
formula
intermediates
Prior art date
Application number
NO985820A
Other languages
English (en)
Other versions
NO985820D0 (no
Inventor
Yoshihisa Yamamoto
Masanori Shindo
Takeshi Nakamura
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO985820D0 publication Critical patent/NO985820D0/no
Publication of NO985820L publication Critical patent/NO985820L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D255/00Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet en cytokinproduksjonsinhibitor omfattende en forbindelse med formel (O N B [U hvor R1 er aryl eller heteroaryl; B er en gruppe med formel (a) eller (b) N ¿ C¿ R / (aj /V2 hvor R2 er hydrogenatom, hydroksy, halogenatom og lignende; R4 er hydrogenatom eller halogenatom, eller R2 og R4 i kombinasjon danner karbonyl; R3 er lavere alkoksy, cykloalkyl, aryl, heteroaryl, -X-Y og lignende, hvor X er -(CH2)m-, -CO-, -COCH2-, -NHCHr, -CH2NH-, -OCH2- og lignende; Y er halogenatom, cykloalkyl, aryl eller hete- roaryl; R51 er -NHCONHR57 og lignende; R52 er hydrogenatom eller -COOR53; A er benzenring eller tiofenring, ny triazepinforbindelse og mellomprodukter for fremstilling av disse triazepinforbindelsene. Forbindelser med formel (I) undertrykker produksjonen av cytokin så som IL-6, TNF-ct, IL-8, IFNy, IL-2, GM-CSF og lignende, og er nyttig som cytokinproduksjonsinhibitorer eller antiinflammatoriske medikamenter.
NO985820A 1996-06-12 1998-12-11 Cytokinproduksjonsinhibitor, triazepinforbindelse og mellomprodukter for disse NO985820L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17426896 1996-06-12
JP9523797 1997-03-28
PCT/JP1997/002016 WO1997047622A1 (fr) 1996-06-12 1997-06-11 Inhibiteurs de production de cytokines, composes triazepine et intermediaires correspondants

Publications (2)

Publication Number Publication Date
NO985820D0 NO985820D0 (no) 1998-12-11
NO985820L true NO985820L (no) 1999-02-01

Family

ID=26436510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985820A NO985820L (no) 1996-06-12 1998-12-11 Cytokinproduksjonsinhibitor, triazepinforbindelse og mellomprodukter for disse

Country Status (9)

Country Link
EP (1) EP0934940A1 (no)
CN (1) CN1227555A (no)
AU (1) AU3106197A (no)
BR (1) BR9710453A (no)
CA (1) CA2258053A1 (no)
IL (1) IL127516A0 (no)
NO (1) NO985820L (no)
PL (1) PL330635A1 (no)
WO (1) WO1997047622A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4071636B2 (ja) * 2001-04-03 2008-04-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 シクロオクタノン誘導体およびシクロデカノン誘導体、およびその用途
US20070238677A1 (en) * 2004-03-17 2007-10-11 Locomogene, Inc. Pharmaceutical Composition Containing Hshrd3
GB0919426D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011054851A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
ES2564318T3 (es) * 2009-11-05 2016-03-21 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
AU2010314395B2 (en) * 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
AU2015203454B2 (en) * 2009-11-05 2017-02-23 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
HUE031073T2 (en) * 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
AU2015201727B2 (en) * 2010-05-14 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
EP2569434B1 (en) 2010-05-14 2019-09-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia and related disorders
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
TWI549955B (zh) * 2010-08-04 2016-09-21 達納 法柏癌症學院有限公司 治療腫瘤形成、發炎疾病及其他病症之組成物及方法
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
CA2881996A1 (en) 2012-08-16 2014-02-20 Bayer Pharma Aktiengesellschaft 2,3-benzodiazepines
ES2625959T3 (es) 2012-09-28 2017-07-21 Bayer Pharma Aktiengesellschaft 5-Aril-triazolo-azepinas inhibidoras de la proteína BET
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3157928B1 (en) 2014-06-20 2019-02-13 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
BR112017006342A2 (pt) * 2014-10-02 2017-12-19 Glaxosmithkline Ip No 2 Ltd composto de sal de ácido benzenossulfônico, forma em estado sólido cristalino, composição farmacêutica, produto farmacêutico de combinação, método de tratamento de doenças ou condições, uso de um composto de sal de ácido benzenossulfônico, e, processo para preparação de um composto de sal de ácido benzenossulfônico.
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181086A1 (es) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc Acetamida tienotrizolodiazepinas y usos de las mismas
WO2017044849A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
EP3518898A4 (en) * 2016-10-03 2020-06-17 The Children's Medical Center Corporation PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY
CA3064845A1 (en) 2017-05-31 2018-12-06 Ayumi Pharmaceutical Corporation 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives
KR20210020889A (ko) * 2018-06-13 2021-02-24 디블라이 아게 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1489979A (en) * 1975-01-20 1977-10-26 Upjohn Co Triazolo benzo-diazepines and triazolo benzodiazocines
US4144233A (en) * 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines
JP2622673B2 (ja) * 1994-11-18 1997-06-18 日本たばこ産業株式会社 骨粗鬆症治療薬およびトリアゼピン化合物
CA2205173A1 (en) * 1994-11-18 1996-05-30 Takeshi Nakamura Therapeutic agent for osteoporosis and triazepine compound

Also Published As

Publication number Publication date
CN1227555A (zh) 1999-09-01
NO985820D0 (no) 1998-12-11
EP0934940A1 (en) 1999-08-11
IL127516A0 (en) 1999-10-28
BR9710453A (pt) 1999-08-17
PL330635A1 (en) 1999-05-24
WO1997047622A1 (fr) 1997-12-18
AU3106197A (en) 1998-01-07
CA2258053A1 (en) 1997-12-18

Similar Documents

Publication Publication Date Title
NO985820L (no) Cytokinproduksjonsinhibitor, triazepinforbindelse og mellomprodukter for disse
DK135791A (da) 1h-imidazooe4,5-caaquinolin-4-amin, farmaceutisk praeparat indeholdende en saadan forbindelse og fremga ngsmaade til fremstilling af forbindelsen
DE69903976T2 (de) Heteroaryl-zyklische acetale
FI935672A0 (fi) Substituerade pyrazoler
DK633088A (da) Kollagenaseinhibitorer
PL307090A1 (en) Derivatives of o-benzyl oxime ether and their application as pesticides
NO986180L (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
EP1468990A4 (en) piperazine derivative
NZ333957A (en) Compounds able to displace tritiated cis-N-cyclohexyl-N-ethyl[3-(3-chloro-4-cyclohexyphenyl)-allyl]amine
MXPA04002570A (es) Compuestos que inhiben la liberacion de citocinas inflamatorias.
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
ES2154605A1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
ES2106936T3 (es) Derivados de carbazolona y procedimientos para su preparacion.
DK0763024T3 (da) Fremgangmåde og mellemprodukter til fremstilling af piperazinderivater
NZ227400A (en) Thiol-ketone and thiol-aldehyde derivatives, intermediates thereof and pharmaceutical compositions
HRP20020440B1 (en) 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
DE3687385D1 (de) 2-substituierte-1,4-dihydropyridine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FI834410A0 (fi) Foerfarande foer framstaellning av pyrimidinonderivat
DK67582A (da) Fremgangsmaade til fremstilling af aroylimidazol-2-oner
CA2203850A1 (en) Novel n-phenyl-n-phenyliminonethylbenzamidines and their analogues as muscarinic receptor agonists
ATE201412T1 (de) Pteridinderivate als no synthase-hemmer
IT1255207B (it) Composizioni farmaceutuche ad attivita' antiaggregante e vasodilatatrice
NO20023513L (no) Anvendelse av et ekstraheringsmiddel som et antiskummiddel ved fremstilling av vannfri maursyre
DE3560829D1 (de) Enkephalinase inhibitors
KR20000016732A (en) Cytokine production inhibitors, triazepine compounds, and intermediates thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application